<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEPHALEXIN- cephalexin powder, for suspension </strong><br>A-S Medication Solutions LLC<br></p></div>
<h1>CEPHALEXIN CAPSULES USP, 250 mg and 500 mg / CEPHALEXIN FOR ORAL SUSPENSION USP, 125 mg/5 mL and 250 mg/5 mL / CEPHALEXIN TABLETS USP, 250 mg and 500 mg<br>3145<br>3147<br>4175<br>4177<br>2238<br>2240<br>Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules, cephalexin for oral suspension, cephalexin tablets, and other antibacterial drugs, cephalexin capsules, cephalexin for oral suspension, and cephalexin tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cephalexin, USP is a semisynthetic cephalosporin antibiotic intended for oral administration. It is 7-(D-α-amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid, monohydrate.</p>
<p>Cephalexin has the following structural formula:</p>
<div class="Figure"><img alt="cephalexin structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c408de52-a15e-49ec-8bcd-eede240e5225&amp;name=4d9aa03f-c465-4dd2-b361-70f46ca77770-01.jpg"></div>
<p>C<span class="Sub">16</span>H<span class="Sub">17</span>N<span class="Sub">3</span>O<span class="Sub">4</span>S•H<span class="Sub">2</span>O          M.W. 365.41</p>
<p>The nucleus of cephalexin is related to that of other cephalosporin antibiotics. The compound is a zwitterion; i.e., the molecule contains both a basic and an acidic group. The isoelectric point of cephalexin in water is approximately 4.5 to 5.</p>
<p>The crystalline form of cephalexin which is available is a monohydrate. It is a white crystalline solid having a bitter taste. Solubility in water is low at room temperature; 1 or 2 mg/mL may be dissolved readily, but higher concentrations are obtained with increasing difficulty.</p>
<p>The cephalosporins differ from penicillins in the structure of the bicyclic ring system. Cephalexin has a <span class="Italics">D</span>-phenylglycyl group as substituent at the 7-amino position and an unsubstituted methyl group at the 3-position.</p>
<p>Each capsule contains cephalexin monohydrate equivalent to 250 mg (720 μmol) or 500 mg (1,439 μmol) of cephalexin.</p>
<p><span class="Bold">Inactive Ingredients: </span>CAPSULES: magnesium stearate, silicon dioxide, and sodium starch glycolate.</p>
<p><span class="Italics">Capsule Shell and Print Constituents: </span>black iron oxide, D&amp;C Yellow #10 Aluminum Lake, FD&amp;C Blue #1 Aluminum Lake, FD&amp;C Blue #2 Aluminum Lake, FD&amp;C Red #40 Aluminum Lake, gelatin, pharmaceutical glaze modified in SD-45, silicon dioxide or carboxymethylcellulose sodium, sodium lauryl sulfate, titanium dioxide and may contain propylene glycol. In addition, the 250 mg capsule shell contains yellow iron oxide.</p>
<p>After mixing, each 5 mL of cephalexin for oral suspension USP will contain cephalexin monohydrate equivalent to 125 mg (360 μmol) or 250 mg (720 μmol) of cephalexin.</p>
<p><span class="Bold">Inactive Ingredients: </span>SUSPENSION: FD&amp;C Red #40, cherry mixed fruit flavor (artificial flavors, benzyl alcohol, maltodextrin, and modified corn starch), silicon dioxide, sodium benzoate, sugar (fruit granulated), and xanthan gum.</p>
<p>Each tablet contains cephalexin monohydrate equivalent to 250 mg (720 μmol) or 500 mg (1,439 μmol) of cephalexin.</p>
<p><span class="Bold">Inactive Ingredients: </span>TABLETS: hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Human Pharmacology</h2>
<p class="First">Cephalexin is acid stable and may be given without regard to meals. It is rapidly absorbed after oral administration. Following doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately 9, 18, and 32 mcg/mL, respectively were obtained at 1 hour. Measurable levels were present 6 hours after administration. Cephalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours. During this period, peak urine concentrations following the 250 mg, 500 mg, and 1 g doses were approximately 1000, 2200, and 5000 mcg/mL, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Microbiology</h2>
<p class="First"><span class="Italics">In vitro </span>tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. Cephalexin has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold">INDICATIONS AND USAGE </span>section.</p>
<p><span class="Underline">Aerobes, Gram-positive:</span></p>
<p><span class="Italics">Staphylococcus aureus </span>(including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Streptococcus pneumoniae </span>(penicillin-susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p><span class="Underline">Aerobes, Gram-negative:</span></p>
<p><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Haemophilus influenzae</span></p>
<p><span class="Italics">Klebsiella pneumoniae</span></p>
<p><span class="Italics">Moraxella (Branhamella) catarrhalis</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Note</span>—Methicillin-resistant staphylococci and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci (<span class="Italics">Enterococcus faecalis </span>[formerly <span class="Italics">Streptococcus faecalis</span>]) are resistant to cephalosporins, including cephalexin. It is not active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterobacter </span>spp., <span class="Italics">Morganella morganii, </span>and <span class="Italics">Proteus vulgaris</span>. It has no activity against <span class="Italics">Pseudomonas </span>spp. or <span class="Italics">Acinetobacter calcoaceticus. </span>Penicillin-resistant <span class="Italics">Streptococcus pneumoniae </span>is usually cross-resistant to beta-lactam antibiotics.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>Susceptibility Tests</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1.1"></a><p></p>
<h4>Dilution techniques</h4>
<p class="First">Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MIC’s). These MIC’s provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC’s should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1-3 </span>(broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cephalothin powder. The MIC values should be interpreted according to the following:</p>
<a name="id_68d11b5c-53ac-46b3-bfbd-228aa62c9177"></a><table width="246">
<caption><span>Interpretive Criteria for Enterobacteriaceae and Staphylococcus spp.:</span></caption>
<col width="53.3%">
<col width="46.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="middle"><span class="Underline"><span class="Bold">MIC (mcg/mL)</span></span></td>
<td class="Botrule Lrule" align="center" valign="middle"><span class="Underline"><span class="Bold">Interpretation</span></span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">≤ 8</td>
<td class="Botrule Lrule" align="center" valign="middle">Susceptible (S)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">16</td>
<td class="Botrule Lrule" align="center" valign="middle">Intermediate (I)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="middle">≥ 32</td>
<td class="Botrule" align="center" valign="middle">Resistant (R)</td>
</tr>
</tbody>
</table>
<p>A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard cephalothin powder should provide the following MIC values:</p>
<a name="id_b4050b5d-e57f-481e-89b8-adf3032bccdd"></a><table width="285">
<col width="51.9%">
<col width="48.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Microorganism</span></span></td>
<td class="Botrule Lrule" align="center" valign="middle"><span class="Bold"><span class="Underline">MIC (mcg/mL)</span></span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Italics">E. coli</span> ATCC 25922</td>
<td class="Botrule Lrule" align="center" valign="middle">4 to 16</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="middle">
<span class="Italics">S. aureus</span> ATCC 29213</td>
<td class="Botrule" align="center" valign="middle">0.12 to 0.5</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1.2"></a><p></p>
<h4>Diffusion techniques</h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3 </span>requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg cephalothin to test the susceptibility of microorganisms to cephalexin.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg cephalothin disk should be interpreted according to the following:</p>
<a name="id_68ac603c-f310-44e1-a0f1-cc45317416c2"></a><table width="NaN">
<caption><span>Interpretive Criteria for Enterobacteriaceae and Staphylococcus spp.:</span></caption>
<col width="NaN%">
<col>
<col width="NaN%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="middle"><span class="Underline"><span class="Bold">Zone Diameter (mm)</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Interpretation</span></span></td>
<td class="Botrule Lrule" align="center" valign="middle"><span class="Underline"><span class="Bold">MIC (mcg/mL)</span></span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">≥ 18</td>
<td class="Botrule Rrule" align="center" valign="middle">Susceptible (S)</td>
<td class="Botrule Lrule" align="center" valign="middle">≤ 8</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">15 to 17</td>
<td class="Botrule Rrule" align="center" valign="middle">Intermediate (I)</td>
<td class="Botrule Lrule" align="center" valign="middle">-</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="middle">≤ 14</td>
<td class="Rrule" align="center" valign="middle">Resistant (R)</td>
<td class="Botrule" align="center" valign="middle">≥ 32</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for cephalexin.</p>
<p>As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30 mcg cephalothin disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a name="id_bc93b9fd-c42b-481f-a27a-a0fbb46a62cf"></a><table width="285">
<col width="51.9%">
<col width="48.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Microorganism</span></span></td>
<td class="Botrule Lrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Zone Range (mm)</span></span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Italics">E. coli</span> ATCC 25922</td>
<td class="Botrule Lrule" align="center" valign="middle">15 to 21</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="middle">
<span class="Italics">S. aureus</span> ATCC 25923</td>
<td class="Botrule" align="center" valign="middle">29 to 37</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cephalexin is indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms:</p>
<p><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Streptococcus pneumoniae </span>and <span class="Italics">Streptococcus pyogenes </span>(Penicillin is the usual drug of choice in the treatment and prevention of <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, including the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available at present.)</p>
<p><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span> due to <span class="Italics">Streptococcus pneumoniae, Haemophilus influenzae</span>, <span class="Italics">Staphylococcus </span><span class="Italics">aureus</span>, <span class="Italics">Streptococcus pyogenes</span>, and <span class="Italics">Moraxella catarrhalis</span></p>
<p>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Staphylococcus </span><span class="Italics">aureus </span>and/or <span class="Italics">Streptococcus pyogenes</span></p>
<p>Bone <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Staphylococcus </span><span class="Italics">aureus </span>and/or <span class="Italics">Proteus mirabilis</span></p>
<p>Genitourinary tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including acute <span class="product-label-link" type="condition" conceptid="194997" conceptname="Prostatitis">prostatitis</span>, caused by <span class="Italics">Escherichia coli, Proteus mirabilis, </span>and <span class="Italics">Klebsiella pneumoniae</span></p>
<p><span class="Italics">Note</span>—Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules, cephalexin for oral suspension, cephalexin tablets, and other antibacterial drugs, cephalexin capsules, cephalexin for oral suspension, and cephalexin tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cephalexin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">BEFORE THERAPY WITH CEPHALEXIN IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEPHALEXIN, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEPHALEXIN OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES AND AIRWAY MANAGEMENT, AS </span><span class="Bold">CLINICALLY INDICATED.</span></p>
<p>There is some clinical and laboratory evidence of partial cross-allergenicity of the penicillins and the cephalosporins. Patients have been reported to have had severe reactions (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to both drugs.</p>
<p>Any patient who has demonstrated some form of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, particularly to drugs, should receive antibiotics cautiously. No exception should be made with regard to cephalexin.</p>
<p><span class="Bold"><span class="Italics">Clostridium difficile</span></span><span class="Bold">associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD)</span> has been reported with use of nearly all antibacterial agents, including cephalexin, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Prescribing cephalexin capsules, cephalexin for oral suspension, or cephalexin tablets in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Patients should be followed carefully so that any side effects or unusual manifestations of drug idiosyncrasy may be detected. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to cephalexin occurs, the drug should be discontinued and the patient treated with the usual agents (e.g., epinephrine or other pressor amines, antihistamines, or corticosteroids).</p>
<p>Prolonged use of cephalexin may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>Positive direct Coombs’ tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs’ testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs’ test may be due to the drug.</p>
<p>Cephalexin should be administered with caution in the presence of markedly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Under such conditions, careful clinical observation and laboratory studies should be made because safe dosage may be lower than that usually recommended.</p>
<p>Indicated surgical procedures should be performed in conjunction with antibiotic therapy.</p>
<p>Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>Cephalosporins may be associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity. Those at risk include patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored in patients at risk and exogenous vitamin K administered as indicated.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including cephalexin capsules, cephalexin for oral suspension, and cephalexin tablets should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When cephalexin capsules, cephalexin for oral suspension, or cephalexin tablets are prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cephalexin capsules, cephalexin for oral suspension, cephalexin tablets, or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Metformin</h3>
<p class="First">In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean C<span class="Sub">max </span>and AUC increased by an average of 34% and 24%, respectively, and metformin mean <span class="product-label-link" type="condition" conceptid="437992" conceptname="Renal function tests abnormal">renal clearance decreased</span> by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.</p>
<p>Although not observed in this study, adverse effects could potentially arise from coadministration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems. Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<h3>Probenecid</h3>
<p class="First">As with other β-lactams, the renal excretion of cephalexin is inhibited by probenecid.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">As a result of administration of cephalexin, a false-positive reaction for glucose in the urine may occur. This has been observed with Benedict’s and Fehling’s solutions and also with Clinitest<span class="Sup">®</span> tablets.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Lifetime studies in animals have not been performed to evaluate the carcinogenic potential of cephalexin. Tests to determine the mutagenic potential of cephalexin have not been performed. In male and female rats, fertility and reproductive performance were not affected by cephalexin oral doses up to 1.5 times the highest recommended human dose based upon mg/m<span class="Sup">2</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6.1.1"></a><p></p>
<h4>Pregnancy category B</h4>
<p class="First">Reproduction studies have been performed on mice and rats using oral doses of cephalexin monohydrate 0.6 and 1.5 times the maximum daily human dose (66 mg/kg/day) based upon mg/m<span class="Sup">2</span>, and have revealed no harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">The excretion of cephalexin in human milk increased up to 4 hours after a 500 mg dose; the drug reached a maximum level of 4 mcg/mL, then decreased gradually, and had disappeared 8 hours after administration. Caution should be exercised when cephalexin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of cephalexin in pediatric patients was established in clinical trials for the dosages described in the <span class="Bold">DOSAGE AND ADMINISTRATION </span>section. In these trials, pediatric patients may have received cephalexin capsules or cephalexin for oral suspension. Cephalexin capsules should only be used in children and adolescents capable of ingesting the capsule.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold">PRECAUTIONS</span>, <span class="Bold">General</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> may occur during or after antibacterial treatment (see <span class="Bold">WARNINGS</span>). <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have been reported rarely. The most frequent side effect has been <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. It was very rarely severe enough to warrant cessation of therapy. <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> have also occurred. As with some penicillins and some other cephalosporins, transient <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> have been reported rarely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">AlIergic reactions in the form of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and, rarely, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, or <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been observed. These reactions usually subsided upon discontinuation of the drug. In some of these reactions, supportive therapy may be necessary. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has also been reported.</p>
<p>Other reactions have included genital and anal <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, genital <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> and <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, and <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorder</span>. Reversible interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> has been reported rarely. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, and slight elevations in AST and ALT have been reported.</p>
<p>In addition to the adverse reactions listed above that have been observed in patients treated with cephalexin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>     Adverse Reactions</h2>
<p class="First">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, renal dysfunction, and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>.</p>
<p>     Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients   <br>     with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced (see <span class="Bold">INDICATIONS AND USAGE<br></span>    and <span class="Bold">PRECAUTIONS</span>, <span class="Bold">General</span>). If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy should occur, the<br>     drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>     Altered Laboratory Tests</h2>
<p class="First">     Prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, increased BUN, increased creatinine, elevated alkaline<br>     phosphatase, elevated bilirubin, elevated LDH, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>To report SUSPECTED ADVERSE EVENTS, contact FDA at 1-800-FDA-1088 or www.fda.gov.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Symptoms of oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>. If other symptoms are present, it is probably secondary to an underlying disease state, an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, or toxicity due to ingestion of a second medication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics">Physicians’ Desk Reference </span>(<span class="Italics">PDR</span>). In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in your patient.</p>
<p>Unless 5 to 10 times the normal dose of cephalexin has been ingested, gastrointestinal decontamination should not be necessary.</p>
<p>Protect the patient’s airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal.</p>
<p>Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of cephalexin; however, it would be extremely unlikely that one of these procedures would be indicated.</p>
<p>The oral median lethal dose of cephalexin in rats is &gt; 5000 mg/kg.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Cephalexin is administered orally.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The adult dosage ranges from 1 to 4 g daily in divided doses. The 333 mg and 750 mg strengths should be administered such that the daily dose is within 1 to 4 grams per day. The usual adult dose is 250 mg every 6 hours. For the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, a dosage of 500 mg may be administered every 12 hours: <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">streptococcal pharyngitis</span>, skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and uncomplicated <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> in patients over 15 years of age. <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span> therapy should be continued for 7 to 14 days. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or those caused by less susceptible organisms, larger doses may be needed. If daily doses of cephalexin greater than 4 g are required, parenteral cephalosporins, in appropriate doses, should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">The usual recommended daily dosage for pediatric patients is 25 to 50 mg/kg in divided doses. For <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">streptococcal pharyngitis</span> in patients over 1 year of age and for skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the total daily dose may be divided and administered every 12 hours.</p>
<a name="id_ef153c04-7945-495b-b6ed-33c6ae40388f"></a><table border="1" width="437">
<col width="27.5%">
<col width="37.8%">
<col width="34.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle">Cephalexin Suspension</td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="Underline">Weight</span></td>
<td class="Botrule" align="left" valign="middle"><span class="Underline">125 mg/5 mL</span></td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="Underline">250 mg/5 mL</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle">10 kg (22 lb)</td>
<td class="Botrule" align="left" valign="middle">1/2 to 1 tsp q.i.d.</td>
<td class="Botrule Rrule" align="left" valign="middle">1/4 to 1/2 tsp q.i.d.</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle">20 kg (44 lb)</td>
<td class="Botrule" align="left" valign="middle">1 to 2 tsp q.i.d.</td>
<td class="Botrule Rrule" align="left" valign="middle">1/2 to 1 tsp q.i.d.</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle">40 kg (88 lb)</td>
<td class="Botrule" align="left" valign="middle">2 to 4 tsp q.i.d.</td>
<td class="Botrule Rrule" align="left" valign="middle">1 to 2 tsp q.i.d.</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"></td>
<td class="Botrule" align="left" valign="middle"><span class="Underline">or</span></td>
<td class="Botrule Rrule" align="left" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle"><span class="Underline">Weight</span></td>
<td class="Botrule" align="left" valign="middle"><span class="Underline">125 mg/5 mL</span></td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="Underline">250 mg/5 mL</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle">10 kg (22 lb)</td>
<td class="Botrule" align="left" valign="middle">1 to 2 tsp b.i.d.</td>
<td class="Botrule Rrule" align="left" valign="middle">1/2 to 1 tsp b.i.d</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="middle">20 kg (44 lb)</td>
<td class="Botrule" align="left" valign="middle">2 to 4 tsp b.i.d.</td>
<td class="Botrule Rrule" align="left" valign="middle">1 to 2 tsp b.i.d.</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="middle">40 kg (88 lb)</td>
<td class="Botrule" align="left" valign="middle">4 to 8 tsp b.i.d.</td>
<td class="Botrule Rrule" align="left" valign="middle">2 to 4 tsp b.i.d.</td>
</tr>
</tbody>
</table>
<p>In severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the dosage may be doubled.</p>
<p>In the therapy of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, clinical studies have shown that a dosage of 75 to 100 mg/kg/day in 4 divided doses is required.</p>
<p>In the treatment of β-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, a therapeutic dosage of cephalexin should be administered for at least 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3"></a><p></p>
<h2>Directions for Mixing</h2>
<p class="First"><span class="Bold">125 mg per 5 mL</span><span class="Bold"> (100 mL when mixed):</span> Prepare suspension at time of dispensing. Add to the bottle a total of 71 mL of water. For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> well after each addition. The resulting suspension will contain cephalexin monohydrate equivalent to 125 mg cephalexin in each 5 mL (teaspoonful). </p>
<p><span class="Bold">125 mg per 5 mL (200 mL when mixed): </span>Prepare suspension at time of dispensing. Add to the bottle a total of 140 mL of water. For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> well after each addition. The resulting suspension will contain cephalexin monohydrate equivalent to 125 mg cephalexin in each 5 mL (teaspoonful).</p>
<p><span class="Bold">250 mg per 5 mL (100 mL when mixed):</span> Prepare suspension at time of dispensing. Add to the bottle a total of 71 mL of water. For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> well after each addition. The resulting suspension will contain cephalexin monohydrate equivalent to 250 mg cephalexin in each 5 mL (teaspoonful). </p>
<p><span class="Bold">250 mg per 5 mL (200 mL when mixed):</span> Prepare suspension at time of dispensing. Add to the bottle a total of 140 mL of water. For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> well after each addition. The resulting suspension will contain cephalexin monohydrate equivalent to 250 mg cephalexin in each 5 mL (teaspoonful). </p>
<p><span class="Sup">*</span> After mixing, store in refrigerator. May be kept for 14 days without significant loss of potency.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Cephalexin capsules USP—</span></p>
<p>250 mg: Swedish orange body and gray cap imprinted “TEVA? on the cap and “3145? on the body, in bottles of 100, 500, and unit-dose boxes of 100 (10 x 10).</p>
<p>500 mg: Swedish orange body and Swedish orange cap imprinted “TEVA? on the cap and “3147? on the body, in bottles of 100, 500, and unit-dose boxes of 100 (10 x 10).</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p><span class="Bold">Cephalexin for oral suspension<span class="Sup">*</span> USP</span></p>
<p>(a cherry mixed fruit flavored formula)—</p>
<p>125 mg/5 mL: bottles of 100 mL and 200 mL.</p>
<p>250 mg/5 mL: bottles of 100 mL and 200 mL.</p>
<p>Directions for mixing are included on the label.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p>Shake well before using. Keep tightly closed.</p>
<p><span class="Sup">*</span> After mixing, store in refrigerator. May be kept for 14 days without significant loss of potency.</p>
<p><span class="Bold">Cephalexin tablets USP—</span></p>
<p>250 mg: bottles of 100. Tablet identification number and color: white, capsule-shaped tablet, debossed “2238? on one side with a score between the “2? and the “3? and “TEVA? on the reverse side.</p>
<p>500 mg: bottles of 100. Tablet identification number and color: white, capsule-shaped tablet, debossed “2240? on one side with a score between the “2? and the “4? and “TEVA? on the reverse side.</p>
<p>Store dry powder at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard-Ninth Edition; Document M07-A9, Vol. 32, No. 2, CLSI, Wayne, PA, January, 2012.</li>
<li>Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Eleventh Edition; Document M02-A11, Vol. 32, No. 1, CLSI, Wayne, PA, January, 2012.</li>
<li>Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Document M100-S22, Vol. 32, No. 3, CLSI, Wayne, PA, January, 2012.</li>
</ol>
<p class="First"><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. Q 1/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-1023-0</span></p>
<p>Relabeled by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="1023-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c408de52-a15e-49ec-8bcd-eede240e5225&amp;name=1023-0.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-1024-0</span></p>
<p>Relabeled by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="1024-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c408de52-a15e-49ec-8bcd-eede240e5225&amp;name=1024-0.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEPHALEXIN 		
					</strong><br><span class="contentTableReg">cephalexin powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-1023(NDC:0093-4175)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEPHALEXIN</strong> (CEPHALEXIN ANHYDROUS) </td>
<td class="formItem">CEPHALEXIN ANHYDROUS</td>
<td class="formItem">125 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY (cherry mixed fruit) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-1023-0</td>
<td class="formItem">200 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062703</td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEPHALEXIN 		
					</strong><br><span class="contentTableReg">cephalexin powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-1024(NDC:0093-4177)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEPHALEXIN</strong> (CEPHALEXIN ANHYDROUS) </td>
<td class="formItem">CEPHALEXIN ANHYDROUS</td>
<td class="formItem">250 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTODEXTRIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY (cherry mixed fruit) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-1024-0</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA062703</td>
<td class="formItem">09/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">relabel(54569-1023, 54569-1024)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f8ade69d-c1a8-4a97-b51f-f0dcfec508e6</div>
<div>Set id: c408de52-a15e-49ec-8bcd-eede240e5225</div>
<div>Version: 1</div>
<div>Effective Time: 20130617</div>
</div>
</div> <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
